Clinical Trial Results, Portfolio Sale Completion, Recognitions, and Conference Schedule - Analyst Notes on Medivation, Endo, Quintiles, Pacira and Lannett

NEW YORK, June 9, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Medivation, Inc. (NASDAQ: MDVN), Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP), Quintiles Transnational Holdings Inc. (NYSE: Q), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) and Lannett Company, Inc. (NYSE: LCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3486-100free.

Medivation, Inc. Analyst Notes
On June 1, 2014, Medivation, Inc. (Medivation), along with Astellas Pharma US, Inc., announced the online publication of the results from the Phase 3 PREVAIL trial, which evaluated the safety and benefit of enzalutamide in men with metastatic prostate cancer progressing despite androgen deprivation therapy. The Company informed that the paper titled "Enzalutamide in Men with Metastatic Prostate Cancer Before Chemotherapy" will be published in the New England Journal of Medicine. "The PREVAIL study results demonstrate that treatment with enzalutamide in men with metastatic castration resistant prostate cancer can decrease the risk of death, delay the growth or spread of metastatic prostate cancer, and delay the time to initiation of chemotherapy," said Tomasz M. Beer, M.D., F.A.C.P., professor of medicine and deputy director of the Knight Cancer Institute at Oregon Health & Science University, and co-principal investigator of the PREVAIL study. The full analyst notes on Medivation are available to download free of charge at:

http://www.analystsreview.com/Jun-09-2014/MDVN/report.pdf

Endo Pharmaceuticals Holdings Inc. Analyst Notes
On June 2, 2014, Endo Pharmaceuticals Holdings Inc. (Endo) announced that its Endo Pharmaceuticals subsidiary has completed the sale of its branded pharmaceutical drug discovery platform to AsanaBioSciences, LLC. The Company stated that the deal includes an upfront payment and milestones on the achievement of certain development objectives. Endo informed that it initiated the exploration of strategic alternatives for the portfolio of early stage drug discovery assets in 2013 as part of its portfolio optimization process. Endo President and CEO Rajiv De Silva commented, "The sale of the early stage discovery platform is another step in the transformation of Endo. We continue to make progress against the strategic objectives we set forth in 2013 and remain enthusiastic about what lies ahead for Endo. We are committed to supporting the organic growth of our existing business segments as we search for attractive acquisition targets to enhance our portfolio of pharmaceutical products." The full analyst notes on Endo are available to download free of charge at:

http://www.analystsreview.com/Jun-09-2014/ENDP/report.pdf

Quintiles Transnational Holdings Inc. Analyst Notes
On June 2, 2014, Quintiles Transnational Holdings Inc. (Quintiles) announced that the Company has been named to the Fortune 500 list of largest U.S. companies ranked by revenue. Commenting on the recognition, Company's CEO Tom Pike stated, "Being named to the Fortune 500 is a significant milestone in Quintiles' history. We operated as a private company for a full decade before returning to the public markets via IPO in 2013. Our inclusion in the Fortune 500 is another indicator that Quintiles is one of the most important companies headquartered in the United States, conducting business in 100 countries." Quintiles stated that companies considered for the Fortune 500 are ranked by total revenues for their respective fiscal years. The full analyst notes on Quintiles are available to download free of charge at:

http://www.analystsreview.com/Jun-09-2014/Q/report.pdf

Pacira Pharmaceuticals Inc. Analyst Notes
On May 27, 2014, Pacira Pharmaceuticals Inc. (Pacira) announced that the Company will participate in the Goldman Sachs 35th Annual Global Healthcare Conference in Rancho Palos Verdes, California. The Company's President, CEO, and Chairman Dave Stack will present company overview at the conference on Wednesday, June 11, 2014, at 10:40 a.m. PT. The presentation will be webcast live via the "Investors & Media" section of the Company's website, where its replay will be archived for two weeks after the presentation. The full analyst notes on Pacira are available to download free of charge at:

http://www.analystsreview.com/Jun-09-2014/PCRX/report.pdf

Lannett Company, Inc. Analyst Notes
On June 2, 2014, Lannett Company, Inc. (Lannett) announced that the Company is set to be added to the S&P SmallCap 600 Index after the close of trading on the date of announcement. The Company's President and CEO Arthur Bedrosian commented, "Lannett's inclusion in the S&P SmallCap 600® Index will help further increase our visibility within the investment community. Our company has delivered excellent financial results, with the most recent quarter representing the sixth consecutive quarter of record net sales. With a deep pipeline, including 19 product applications currently pending at FDA, we are well positioned for continued long-term growth." The full analyst notes on Lannett are available to download free of charge at:

http://www.analystsreview.com/Jun-09-2014/LCI/report.pdf

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review